Navigation Links
Three Nephrology TreatmentTrends Publications from BioTrends Provide a Comprehensive View of Bone and Mineral Metabolism Practice Patterns Around the Globe
Date:1/16/2010

increase as Renvela becomes more widely available in the EU markets. In the US market, the conversion from Renagel to Renvela has already been quite strong with over 90% of Nephrologists now prescribing the product and sevelamer share division favoring Renvela over Renagel.

In the PTH modifier market, there are a number of regional variations. The availability and use of active vitamin D brands, for example, differs, with Abbott's Zemplar holding the market leader position among hemodialysis patients in the US and Spain, whereas in Canada calcitriol holds the market leader position in both dialysis and CKD-ND. Alfacalcidiol leads the market in the UK, whereas in Germany, calcitriol and alfacalcidiol almost evenly divide the market. There are also differences by region in terms of when active vitamin D should be used - only when PTH is elevated or in low doses, regardless of PTH. There are however, some market similarities. In both the US and Europe, the use of nutritional vitamin D is projected to increase. In all markets, use of Amgen's Sensipar / Mimpara tends to be limited to dialysis patients. Use of Sensipar / Mimpara is, however, higher in the US than in Europe overall, but use in the US has been relatively flat while use in Europe has been growing. There are significant differences though in uptake of the product within Europe from a low of 9% market share in the UK to more than one-third of patients on the product in Spain. It will be interesting to see the bone and mineral metabolism market continue to evolve, particularly with the release of the KDIGO CKD-MBD guideline, which a number of Nephrologists believe will positively impact their use of phosphate binders, active vitamin D and cinacalcet.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (

SOURCE BioTrends Research Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. China Yongxin Pharmaceuticals Opened Three New Stores in 2009 and Expanded Customer Base
2. Multi-Billion Dollar Biotech Firm Chooses Lionbridge as Exclusive Translation Provider with Three-Year Master Services Agreement
3. Millipore Sponsors Three Academic Memberships for the MetaMiner Stem Cell Project
4. Laureate Pharma Welcomes Three New Members to Business Development Team
5. ViroPharma to Present at Three November Healthcare Conferences
6. Safety in Drinking Water? Monitoring for Radioactive Contaminants Only Required Every Three, Six, or Nine Years per Federal Law
7. Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine
8. Virginia Now Owns Three Top National Business Rankings
9. Michigan Pre-Seed Capital Fund Awards Three Micro Loans
10. Poniard Pharmaceuticals To Present at Three Upcoming Investor Conferences in September
11. OmniComm Systems Inc. Expands Its Successful CRO Preferred Program(TM) By Signing On Three New CRO Partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015 PRC Clinical, a ... Francisco Bay Area, will exhibit and present at the ... on March 25th and 26th in Tel Aviv, ... with Israeli life science companies seeking to conduct U.S. ... services span all phases of human trials, from Phase ...
(Date:3/4/2015)... 4, 2015  BioClinica®, Inc., a leading ... today announced that clinical trial professionals representing ... its annual European User Conference in ... the use of its eClinical technologies to ... include: the Microsoft Office-Smart OnPoint CTMS; Express ...
(Date:3/4/2015)... PARIS , March 4, 2015 ... de Paris in December 2011, ... study of yttrium-90 resin microspheres versus sorafenib in advanced ... results expected late 2016.   SARAH, a ... liver cancer (hepatocellular carcinoma, or HCC) has completed patient ...
(Date:3/3/2015)... 3, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, ... molecular diagnostics that target the underlying mechanisms of cancer, ... period ended December 31, 2014. Effective July ... from May 31 to December 31. As a result ... are for the quarter and the seven months ended ...
Breaking Biology Technology:PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... INSM ), a developer of follow-on biologics ... announced today that it has,entered into a definitive agreement ... will purchase all assets related to Insmed,s follow-on,biologics platform. ... receive a,total of $130 million for the assets. ...
... SAN DIEGO, Feb. 11 BioMed Realty Trust, Inc. ... of a refinancing of the secured acquisition and interim ... its joint venture with a fund managed by Prudential ... 600,000 square feet of life science space in Cambridge, ...
... Inc. ("OriGene") today announced it has raised an ... With this financing, OriGene completed the acquisition of ... a manufacturer and provider of monoclonal antibodies (mAb) ... completes the establishment of its technology center to ...
Cached Biology Technology:Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million 2Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million 3Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million 4BioMed Realty Trust Announces New Financing for Joint Venture With Prudential Real Estate Investors 2BioMed Realty Trust Announces New Financing for Joint Venture With Prudential Real Estate Investors 3BioMed Realty Trust Announces New Financing for Joint Venture With Prudential Real Estate Investors 4OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China 2
(Date:3/2/2015)... 2, 2015   Neurotechnology , a provider of ... SentiGaze Software Development Kit (SDK). The SentiGaze ... use off-the-shelf webcams to track eye movements and generate ... monitor. Heatmaps can be used for applications such as ... advertising. The SDK can also be used to develop ...
(Date:2/24/2015)... NEW YORK , Feb. 24, 2015 This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... America . Annual estimates and forecasts are provided for ... is provided for these markets. Market data and analytics are ...
(Date:2/24/2015)... , Feb. 24, 2015 Research and ... the addition of the "Global 2D Gesture ... The analysts forecast the Global ... CAGR of 32.12% over the period 2014-2019 ... in non-traditional sectors is one of the major ...
Breaking Biology News(10 mins):Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2
... of Energy has granted more than $1.8 million to a researcher looking ... 18 months, almost $2 million more will be given to transfer the ... "The goal of our ... world in terms of energy and research," said Dr. Joshua Yuan, Texas ...
... Yale-led study of the evolutionary history of Antarctic fish and ... ago a lineage of fish adapted to newly formed polar ... rapid rise in ocean temperatures. , "A rise of 2 ... impact on this Antarctic fish lineage, which is so well ...
... from the University of Notre Dame, the University of Iowa ... million from the National Science Foundation to answer a fundamental ... extent, do other species that depend on it evolve as ... a fruit fly specifically the apple maggot fly ...
Cached Biology News:US Energy Department grants $1.87 million for plant fuel project 2Fish of Antarctica threatened by climate change 2Notre Dame biologists tackling big question in evolution 2
... is a rugged, compact, lab-quality ... information you need - at ... of gas mixtures is critical, ... generates more data in less ...
The novel and unique HCTplus delivers unmatched information-rich data-dependent LC/MSn data for todays challenge in proteomics and metabonomics work....
... Plus is a small and ... market for both LC and IC. It ... Atmospheric Pressure Ionization (API) source for outstanding ... is compatible with existing LC and IC ...
... call for critical, but time-consuming optimization ... siRNA transfection protocols resulting in less ... be used to efficiently transfect adherent ... without increased cytotoxicity. From start to ...
Biology Products: